AustralieFrV1, PascalFrancis, Corpus, bibRecord, 004937

Atypical mood stabilizers: a 'typical' role for atypical antipsychotics

Identifieur interne : 004937 ( PascalFrancis/Corpus ); précédent : 004936; suivant : 004938

Atypical mood stabilizers: a 'typical' role for atypical antipsychotics

Auteurs : G. S. Malhi ; M. Berk ; M. Bourin ; B. Ivanovski ; S. Dodd ; J. Lagopoulos ; P. B. Mitchell

Source :

Acta psychiatrica scandinavica. Supplementum [ 0065-1591 ] ; 2005.

RBID : Pascal:05-0265817

Descripteurs français

Pascal (Inist)
- Normothymique, Psychotrope, Chimiothérapie, Antipsychotique atypique, Traitement, Trouble bipolaire, Efficacité traitement, Article synthèse, Homme.

English descriptors

KwdEn :
- Atypical antipsychotic, Bipolar disorder, Chemotherapy, Human, Mood stabilizer, Psychotropic, Review, Treatment, Treatment efficiency.

Abstract

Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0065-1591`
A02	`01`			`@0 ASSUA6`
A03		`1`		`@0 Acta psychiatr. scand., Suppl.`
A05				`@2 111`
A06				`@2 426`
A08	`01`	`1`	`ENG`	`@1 Atypical mood stabilizers: a 'typical' role for atypical antipsychotics`
A09	`01`	`1`	`ENG`	`@1 Mood stabilizers: a labile label`
A11	`01`	`1`		`@1 MALHI (G. S.)`
A11	`02`	`1`		`@1 BERK (M.)`
A11	`03`	`1`		`@1 BOURIN (M.)`
A11	`04`	`1`		`@1 IVANOVSKI (B.)`
A11	`05`	`1`		`@1 DODD (S.)`
A11	`06`	`1`		`@1 LAGOPOULOS (J.)`
A11	`07`	`1`		`@1 MITCHELL (P. B.)`
A12	`01`	`1`		`@1 MALHI (G. S.) @9 ed.`
A12	`02`	`1`		`@1 MITCHELL (P. B.) @9 ed.`
A12	`03`	`1`		`@1 BERK (M.) @9 ed.`
A12	`04`	`1`		`@1 GOODWIN (G. M.) @9 ed.`
A14	`01`			`@1 Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital @2 Sydney @3 AUS @Z 1 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut.`
A14	`02`			`@1 School of Psychiatry, University of New South Wales @2 Sydney @3 AUS @Z 1 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut.`
A14	`03`			`@1 Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute @2 Sydney @3 AUS @Z 1 aut. @Z 6 aut.`
A14	`04`			`@1 Department of Clinical and Biomedical Sciences, The University of Melbourne @2 Melbourne @3 AUS @Z 2 aut. @Z 5 aut.`
A14	`05`			`@1 Community and Mental Health, Barwon Health @2 Geelong @3 AUS @Z 2 aut. @Z 5 aut.`
A14	`06`			`@1 Drygen Research Centre @2 Parkville @3 AUS @Z 2 aut.`
A14	`07`			`@1 Faculté de Médecine, Université de Nantes @2 Nantes @3 FRA @Z 3 aut.`
A15	`01`			`@1 Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital, University of New South Wales @2 Sydney, NSW @3 AUS @Z 1 aut. @Z 2 aut.`
A15	`02`			`@1 School of Psychiatry, University of New South Wales @2 Sydney, NSW @3 USA @Z 1 aut. @Z 2 aut.`
A15	`03`			`@1 Department of Clinical and Biomedical Sciences, The University of Melbourne @2 Melbourne @3 AUS @Z 3 aut.`
A15	`04`			`@1 Community and Mental Health, Barwon Health @2 Geelong @3 AUS @Z 3 aut.`
A15	`05`			`@1 Orygen Research Centre @2 Parkville @3 AUS @Z 3 aut.`
A15	`06`			`@1 University Department of Psychiatry, Warnford Hospital @2 Oxford @3 GBR @Z 4 aut.`
A20				`@1 29-38`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3204B @5 354000125344190040`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 95 ref.`
A47	`01`	`1`		`@0 05-0265817`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Acta psychiatrica scandinavica. Supplementum`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.
C02	`01`	`X`		`@0 002B02B02`
C03	`01`	`X`	`FRE`	`@0 Normothymique @5 01`
C03	`01`	`X`	`ENG`	`@0 Mood stabilizer @5 01`
C03	`01`	`X`	`SPA`	`@0 Estabilizador humor @5 01`
C03	`02`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 02`
C03	`02`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 02`
C03	`02`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 02`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 03`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 03`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 03`
C03	`04`	`X`	`FRE`	`@0 Antipsychotique atypique @5 04`
C03	`04`	`X`	`ENG`	`@0 Atypical antipsychotic @5 04`
C03	`04`	`X`	`SPA`	`@0 Antipsicótico atípico @5 04`
C03	`05`	`X`	`FRE`	`@0 Traitement @5 05`
C03	`05`	`X`	`ENG`	`@0 Treatment @5 05`
C03	`05`	`X`	`SPA`	`@0 Tratamiento @5 05`
C03	`06`	`X`	`FRE`	`@0 Trouble bipolaire @5 06`
C03	`06`	`X`	`ENG`	`@0 Bipolar disorder @5 06`
C03	`06`	`X`	`SPA`	`@0 Trastorno bipolar @5 06`
C03	`07`	`X`	`FRE`	`@0 Efficacité traitement @5 07`
C03	`07`	`X`	`ENG`	`@0 Treatment efficiency @5 07`
C03	`07`	`X`	`SPA`	`@0 Eficacia tratamiento @5 07`
C03	`08`	`X`	`FRE`	`@0 Article synthèse @5 08`
C03	`08`	`X`	`ENG`	`@0 Review @5 08`
C03	`08`	`X`	`SPA`	`@0 Artículo síntesis @5 08`
C03	`09`	`X`	`FRE`	`@0 Homme @5 18`
C03	`09`	`X`	`ENG`	`@0 Human @5 18`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 18`
C07	`01`	`X`	`FRE`	`@0 Trouble humeur @5 37`
C07	`01`	`X`	`ENG`	`@0 Mood disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Trastorno humor @5 37`
N21				`@1 185`

Format Inist (serveur)

NO :	PASCAL 05-0265817 INIST
ET :	Atypical mood stabilizers: a 'typical' role for atypical antipsychotics
AU :	MALHI (G. S.); BERK (M.); BOURIN (M.); IVANOVSKI (B.); DODD (S.); LAGOPOULOS (J.); MITCHELL (P. B.); MALHI (G. S.); MITCHELL (P. B.); BERK (M.); GOODWIN (G. M.)
AF :	Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital/Sydney/Australie (1 aut., 4 aut., 6 aut., 7 aut.); School of Psychiatry, University of New South Wales/Sydney/Australie (1 aut., 4 aut., 6 aut., 7 aut.); Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute/Sydney/Australie (1 aut., 6 aut.); Department of Clinical and Biomedical Sciences, The University of Melbourne/Melbourne/Australie (2 aut., 5 aut.); Community and Mental Health, Barwon Health/Geelong/Australie (2 aut., 5 aut.); Drygen Research Centre/Parkville/Australie (2 aut.); Faculté de Médecine, Université de Nantes/Nantes/France (3 aut.); Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital, University of New South Wales/Sydney, NSW/Australie (1 aut., 2 aut.); School of Psychiatry, University of New South Wales/Sydney, NSW/Etats-Unis (1 aut., 2 aut.); Department of Clinical and Biomedical Sciences, The University of Melbourne/Melbourne/Australie (3 aut.); Community and Mental Health, Barwon Health/Geelong/Australie (3 aut.); Orygen Research Centre/Parkville/Australie (3 aut.); University Department of Psychiatry, Warnford Hospital/Oxford/Royaume-Uni (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Acta psychiatrica scandinavica. Supplementum; ISSN 0065-1591; Coden ASSUA6; Royaume-Uni; Da. 2005; Vol. 111; No. 426; Pp. 29-38; Bibl. 95 ref.
LA :	Anglais
EA :	Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.
CC :	002B02B02
FD :	Normothymique; Psychotrope; Chimiothérapie; Antipsychotique atypique; Traitement; Trouble bipolaire; Efficacité traitement; Article synthèse; Homme
FG :	Trouble humeur
ED :	Mood stabilizer; Psychotropic; Chemotherapy; Atypical antipsychotic; Treatment; Bipolar disorder; Treatment efficiency; Review; Human
EG :	Mood disorder
SD :	Estabilizador humor; Psicotropo; Quimioterapia; Antipsicótico atípico; Tratamiento; Trastorno bipolar; Eficacia tratamiento; Artículo síntesis; Hombre
LO :	INIST-3204B.354000125344190040
ID :	05-0265817

Links to Exploration step

Pascal:05-0265817

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Atypical mood stabilizers: a 'typical' role for atypical antipsychotics</title>
<author><name sortKey="Malhi, G S" sort="Malhi, G S" uniqKey="Malhi G" first="G. S." last="Malhi">G. S. Malhi</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M." last="Berk">M. Berk</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Clinical and Biomedical Sciences, The University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Community and Mental Health, Barwon Health</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Drygen Research Centre</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bourin, M" sort="Bourin, M" uniqKey="Bourin M" first="M." last="Bourin">M. Bourin</name>
<affiliation><inist:fA14 i1="07"><s1>Faculté de Médecine, Université de Nantes</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ivanovski, B" sort="Ivanovski, B" uniqKey="Ivanovski B" first="B." last="Ivanovski">B. Ivanovski</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dodd, S" sort="Dodd, S" uniqKey="Dodd S" first="S." last="Dodd">S. Dodd</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Clinical and Biomedical Sciences, The University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Community and Mental Health, Barwon Health</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lagopoulos, J" sort="Lagopoulos, J" uniqKey="Lagopoulos J" first="J." last="Lagopoulos">J. Lagopoulos</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mitchell, P B" sort="Mitchell, P B" uniqKey="Mitchell P" first="P. B." last="Mitchell">P. B. Mitchell</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0265817</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0265817 INIST</idno>
<idno type="RBID">Pascal:05-0265817</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004937</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Atypical mood stabilizers: a 'typical' role for atypical antipsychotics</title>
<author><name sortKey="Malhi, G S" sort="Malhi, G S" uniqKey="Malhi G" first="G. S." last="Malhi">G. S. Malhi</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M." last="Berk">M. Berk</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Clinical and Biomedical Sciences, The University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Community and Mental Health, Barwon Health</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Drygen Research Centre</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bourin, M" sort="Bourin, M" uniqKey="Bourin M" first="M." last="Bourin">M. Bourin</name>
<affiliation><inist:fA14 i1="07"><s1>Faculté de Médecine, Université de Nantes</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ivanovski, B" sort="Ivanovski, B" uniqKey="Ivanovski B" first="B." last="Ivanovski">B. Ivanovski</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dodd, S" sort="Dodd, S" uniqKey="Dodd S" first="S." last="Dodd">S. Dodd</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Clinical and Biomedical Sciences, The University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Community and Mental Health, Barwon Health</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lagopoulos, J" sort="Lagopoulos, J" uniqKey="Lagopoulos J" first="J." last="Lagopoulos">J. Lagopoulos</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mitchell, P B" sort="Mitchell, P B" uniqKey="Mitchell P" first="P. B." last="Mitchell">P. B. Mitchell</name>
<affiliation><inist:fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Acta psychiatrica scandinavica. Supplementum</title>
<title level="j" type="abbreviated">Acta psychiatr. scand., Suppl.</title>
<idno type="ISSN">0065-1591</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Acta psychiatrica scandinavica. Supplementum</title>
<title level="j" type="abbreviated">Acta psychiatr. scand., Suppl.</title>
<idno type="ISSN">0065-1591</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atypical antipsychotic</term>
<term>Bipolar disorder</term>
<term>Chemotherapy</term>
<term>Human</term>
<term>Mood stabilizer</term>
<term>Psychotropic</term>
<term>Review</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Normothymique</term>
<term>Psychotrope</term>
<term>Chimiothérapie</term>
<term>Antipsychotique atypique</term>
<term>Traitement</term>
<term>Trouble bipolaire</term>
<term>Efficacité traitement</term>
<term>Article synthèse</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0065-1591</s0>
</fA01>
<fA02 i1="01"><s0>ASSUA6</s0>
</fA02>
<fA03 i2="1"><s0>Acta psychiatr. scand., Suppl.</s0>
</fA03>
<fA05><s2>111</s2>
</fA05>
<fA06><s2>426</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Atypical mood stabilizers: a 'typical' role for atypical antipsychotics</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Mood stabilizers: a labile label</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>MALHI (G. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BERK (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BOURIN (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>IVANOVSKI (B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DODD (S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LAGOPOULOS (J.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MITCHELL (P. B.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>MALHI (G. S.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>MITCHELL (P. B.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>BERK (M.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="04" i2="1"><s1>GOODWIN (G. M.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Clinical and Biomedical Sciences, The University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Community and Mental Health, Barwon Health</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Drygen Research Centre</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Faculté de Médecine, Université de Nantes</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital, University of New South Wales</s1>
<s2>Sydney, NSW</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>School of Psychiatry, University of New South Wales</s1>
<s2>Sydney, NSW</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Department of Clinical and Biomedical Sciences, The University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>Community and Mental Health, Barwon Health</s1>
<s2>Geelong</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA15 i1="05"><s1>Orygen Research Centre</s1>
<s2>Parkville</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA15 i1="06"><s1>University Department of Psychiatry, Warnford Hospital</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</fA15>
<fA20><s1>29-38</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3204B</s2>
<s5>354000125344190040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>95 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0265817</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Acta psychiatrica scandinavica. Supplementum</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Normothymique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Mood stabilizer</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estabilizador humor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antipsychotique atypique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Atypical antipsychotic</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antipsicótico atípico</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Trouble bipolaire</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Bipolar disorder</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Trastorno bipolar</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Review</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble humeur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>37</s5>
</fC07>
<fN21><s1>185</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 05-0265817 INIST</NO>
<ET>Atypical mood stabilizers: a 'typical' role for atypical antipsychotics</ET>
<AU>MALHI (G. S.); BERK (M.); BOURIN (M.); IVANOVSKI (B.); DODD (S.); LAGOPOULOS (J.); MITCHELL (P. B.); MALHI (G. S.); MITCHELL (P. B.); BERK (M.); GOODWIN (G. M.)</AU>
<AF>Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital/Sydney/Australie (1 aut., 4 aut., 6 aut., 7 aut.); School of Psychiatry, University of New South Wales/Sydney/Australie (1 aut., 4 aut., 6 aut., 7 aut.); Mayne Clinical Research Imaging Centre, Prince of Wales Medical Research Institute/Sydney/Australie (1 aut., 6 aut.); Department of Clinical and Biomedical Sciences, The University of Melbourne/Melbourne/Australie (2 aut., 5 aut.); Community and Mental Health, Barwon Health/Geelong/Australie (2 aut., 5 aut.); Drygen Research Centre/Parkville/Australie (2 aut.); Faculté de Médecine, Université de Nantes/Nantes/France (3 aut.); Mood Disorders Unit, Black Dog Institute, Prince of Wales Hospital, University of New South Wales/Sydney, NSW/Australie (1 aut., 2 aut.); School of Psychiatry, University of New South Wales/Sydney, NSW/Etats-Unis (1 aut., 2 aut.); Department of Clinical and Biomedical Sciences, The University of Melbourne/Melbourne/Australie (3 aut.); Community and Mental Health, Barwon Health/Geelong/Australie (3 aut.); Orygen Research Centre/Parkville/Australie (3 aut.); University Department of Psychiatry, Warnford Hospital/Oxford/Royaume-Uni (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Acta psychiatrica scandinavica. Supplementum; ISSN 0065-1591; Coden ASSUA6; Royaume-Uni; Da. 2005; Vol. 111; No. 426; Pp. 29-38; Bibl. 95 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: To assess the potential role of atypical antipsychotics as mood stabilizers. Method: A MedLine, PsychLIT, PubMed, and EMBASE literature search of papers published up to December 2004 was conducted using the names of atypical antipsychotics and a number of key terms relevant to bipolar disorder. Additional articles were retrieved by scrutinizing the bibliographies of review papers and literature known to the authors. Data pertinent to the objective was reviewed according to the various phases of bipolar disorder. Results: The data is most substantive for the use of atypical antipsychotics in mania, to the extent that an argument for a class effect of significant efficacy can be made. This does not extend to bipolar depression, however, good data is now emerging for some agents and will need to be considered for each individual agent as it accumulates. As regards mixed states and rapid cycling the evidence is thus far sparse and too few maintenance studies have been conducted to make any firm assertions. However, with respect to long-term therapy the atypical antipsychotics do have clinically significant side-effects of which clinicians need to be aware. Conclusion: Based on the evidence thus far it is perhaps premature to describe the atypical antipsychotics as mood stabilizers. Individual agents may eventually be able to claim this label, however, much further research is needed especially with respect to maintenance and relapse prevention.</EA>
<CC>002B02B02</CC>
<FD>Normothymique; Psychotrope; Chimiothérapie; Antipsychotique atypique; Traitement; Trouble bipolaire; Efficacité traitement; Article synthèse; Homme</FD>
<FG>Trouble humeur</FG>
<ED>Mood stabilizer; Psychotropic; Chemotherapy; Atypical antipsychotic; Treatment; Bipolar disorder; Treatment efficiency; Review; Human</ED>
<EG>Mood disorder</EG>
<SD>Estabilizador humor; Psicotropo; Quimioterapia; Antipsicótico atípico; Tratamiento; Trastorno bipolar; Eficacia tratamiento; Artículo síntesis; Hombre</SD>
<LO>INIST-3204B.354000125344190040</LO>
<ID>05-0265817</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004937 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 004937 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0265817
   |texte=   Atypical mood stabilizers: a 'typical' role for atypical antipsychotics
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Atypical mood stabilizers: a 'typical' role for atypical antipsychotics

Atypical mood stabilizers: a 'typical' role for atypical antipsychotics

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri